Clinical Trial Update: An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial of ustekinumab in active nonradiographic axial spondyloarthritis was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Nonradiographic Axial Spondylitis

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Nonradiographic Axial Spondylitis, Ankylosing | Phase 3 | Status: TERMINATED | Results posted: 2019-03-13